| Literature DB >> 24352040 |
Jan Fischer1, Zhihong Wu1, Tomasz Kantyka2, Maria Sperrhacke1, Olga Dimitrieva1, Yulia Koblyakova1, Kerstin Ahrens1, Nina Graumann1, Hansjörg Baurecht1, Karina Reiss1, Jens-Michael Schröder1, Ehrhardt Proksch1, Ulf Meyer-Hoffert3.
Abstract
The proteolytic regulation of the desquamation process by kallikrein-related peptidases (KLKs) is crucial for epidermal barrier function, and elevated KLK levels have been reported in atopic dermatitis. KLKs are controlled by specific inhibitors of the serine protease inhibitor of Kazal-type (Spink) family. Recently, SPINK6 was shown to be present in human stratum corneum. In order to investigate its role in epidermal barrier function, we studied mouse Spink6. Sequence alignment revealed that the Kazal domain of Spink6 is highly conserved in animals. Recombinant Spink6 efficiently inhibited mouse Klk5 and human KLK2, KLK4, KLK5, KLK6, KLK7, KLK12, KLK13, and KLK14, whereas human KLK1 and KLK8 were not inhibited. Spink6 was expressed in mouse epidermis mainly in the stratum granulosum, and the inner root sheath of hair follicles. Stimulation with flagellin, EGF, and IL-1β did not alter Spink6 expression, whereas stimulation with tumor necrosis factor-α (TNFα)/IFNγ and all-trans retinoic acid resulted in a significant downregulation of Spink6 expression in cultured primary mouse keratinocytes. Mechanically and metabolically induced skin barrier dysfunction resulted both in a downregulation of Spink6 expression. Our study indicates that Spink6 is a potent inhibitor of KLKs and involved in skin barrier function.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24352040 DOI: 10.1038/jid.2013.502
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551